News
The MUHC Authorizes an AstraZeneca Study on Metastatic Lung Cancer in 8 Weeks and Recruits the First Patient in the World
The MUHC Authorizes an AstraZeneca Study on Metastatic Lung Cancer in 8 Weeks and Recruits the First Patient in the World With the support of the FAST TRACK Evaluation Service coordinated by CATALIS Quebec, the McGill University Health Centre (MUHC) was able to obtain authorization in 8 weeks for the ARTEMIDE-Lung03 study conducted by AstraZeneca, and was able to
Amgen Canada Obtains Authorization in 8 Weeks for Its First FAST TRACK Study on Lung Cancer at the McGill University Health Centre, Making It the First Site Activated in Canada in 9.8 weeks
Amgen Canada Obtains Authorization in 8 Weeks for Its First FAST TRACK Study on Lung Cancer at the McGill University Health Centre, Making It the First Site Activated in Canada in 9.8 weeks Amgen Canada used CATALIS Quebec’s FAST TRACK Evaluation Service for its 20230153 Phase II study on non-small cell lung cancer (NSCLC). Through this initiative, the research
Two Clinical Trials on Asthma Conducted by Sanofi Are Authorized in a Record Median Time of 6.7 Weeks at the CHUS, With the Support of the Fast Track Evaluation Service
Two Clinical Trials on Asthma Conducted by Sanofi Are Authorized in a Record Median Time of 6.7 Weeks at the CHUS, With the Support of the Fast Track Evaluation Service Sanofi used CATALIS’ FAST TRACK Evaluation Service for two Phase II studies, AIRCULES and AIRLYMPUS, focusing on asthma. The research team led by Dr. Simon Couillard of the Centre for
6 New Members Join the CATALIS Network
6 New Members Join the CATALIS Network CATALIS is proud to welcome four new HSSIs, one new pharmaceutical company, and one new patient organization that have just joined its extensive Network of partners. 4 New HSSIs Join the CATALIS Network CATALIS Quebec is proud to announce that the reach of its services now extends to 27 institutions
3 New Members on the CATALIS’ Board of Directors
3 New Members on the CATALIS’ Board of Directors CATALIS is pleased to announce the appointments of Alain Couture, Natalie Verreault and Patrick Montpetit to the Board of Directors as board members. The Board of Directors Welcomes Alain Couture “It is with great pleasure that I join the CATALIS Board of Directors. I am eager to
Update on Bill 5: New Tools Available for Health Institutions
Update on Bill 5: New Tools Available for Health Institutions As part of its government mandate to optimize the clinical research environment in Quebec, CATALIS supports provincial efforts that focus on the implementation of the Bill 5 on health and social services information (AHSSI or Bill 5) . Its objective is to facilitate effective access to health information for
Five New Health Institutions Join the FAST TRACK Evaluation Service
Five New Health Institutions Join the FAST TRACK Evaluation Service The CATALIS Network continues to grow and collaborate to accelerate clinical research in Quebec. We proudly announce that five new health and social services institutions (HSSIs) will soon offer the FAST TRACK Evaluation Service. The CISSS de Lanaudière, the CISSS des Laurentides, the CISSS de Laval, the CISSS de
The CHUM Authorizes a Novartis Study on Prostate Cancer With the Support of the FAST TRACK Evaluation Service and Recruits the First Patient Worldwide
The CHUM Authorizes a Novartis Study on Prostate Cancer With the Support of the FAST TRACK Evaluation Service and Recruits the First Patient Worldwide Novartis used the FAST TRACK Evaluation Service for its phase III study, PSMA-DC, which aims to assess the efficacy and safety of lutetium vipivotide tetraxetan (AAA617) in patients whose prostate cancer has advanced to an
The CHU de Québec-Université Laval Recruits the First Two Participants Worldwide for a Clinical Trial on Breast Cancer by Roche, With the Support of the FAST TRACK Evaluation Service
The CHU de Québec-Université Laval Recruits the First Two Participants Worldwide for a Clinical Trial on Breast Cancer by Roche, With the Support of the FAST TRACK Evaluation Service The research team led by Dr. Julie Lemieux of CHU de Québec-Université Laval recently recruited the first two participants worldwide for a phase III breast cancer study. With the support
Montreal’s Jewish General Hospital Authorized the First BMS Study in 8.6 Weeks and Is the Most Rapidly Activated Site in Canada
Montreal’s Jewish General Hospital Authorized the First BMS Study in 8.6 Weeks and Is the Most Rapidly Activated Site in Canada The Bristol Mayers Squibb (BMS) pharmaceutical company used the FAST TRACK Evaluation Service for the first time, which led to the Jewish General Hospital’s Dr. Sarit Assouline’s research team to obtain authorization for the CA235-0001 study in a